Novo Nordisk AS
NVO
Company Profile
Business description
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Contact
Novo Alle 1
Bagsvaerd2880
DNKT: +45 44448888
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
69,500
Novo Nordisk AS News & Analysis
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Why Pfizer and Roche look like top choices for investors in the war to tip the scales.
markets
December 2025 US stock market outlook: Where we see investment opportunities
Heading into year-end, Santa Claus Rally or AI exhaustion?
stocks
3 ‘buy the dip’ candidates with wide moats
Does recent share price weakness spell opportunity in these three high-quality companies?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,829.50 | 17.30 | 0.20% |
| CAC 40 | 7,981.76 | 5.73 | -0.07% |
| DAX 40 | 24,400.65 | 92.73 | 0.38% |
| Dow JONES (US) | 49,526.66 | 159.46 | -0.32% |
| FTSE 100 | 10,330.55 | 6.80 | 0.07% |
| HKSE | 25,797.85 | 122.67 | 0.48% |
| NASDAQ | 25,977.16 | 113.58 | -0.44% |
| Nikkei 225 | 60,550.59 | 265.36 | -0.44% |
| NZX 50 Index | 12,974.32 | 211.40 | 1.66% |
| S&P 500 | 7,379.46 | 23.59 | -0.32% |
| S&P/ASX 200 | 8,604.70 | 23.10 | 0.27% |
| SSE Composite Index | 4,169.54 | 38.01 | 0.92% |